These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 15738451)

  • 21. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study.
    Herman WH
    Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
    Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
    Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
    J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.
    Ann Intern Med; 2005 Aug; 143(4):I22. PubMed ID: 16103465
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economics of diabetes prevention.
    Herman WH
    Med Clin North Am; 2011 Mar; 95(2):373-84, viii. PubMed ID: 21281839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
    Bertram MY; Lim SS; Barendregt JJ; Vos T
    Diabetologia; 2010 May; 53(5):875-81. PubMed ID: 20135088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study.
    Liu X; Li C; Gong H; Cui Z; Fan L; Yu W; Zhang C; Ma J
    BMC Public Health; 2013 Aug; 13():729. PubMed ID: 23919839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
    Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X; Vondeling H
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of metformin for diabetes prevention.
    Slama G
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S104-11. PubMed ID: 14502107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
    Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
    BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model-A multiregional case study.
    Al-Omar HA; Czech M; Quang Nam T; Gottwald-Hostalek U; Vesic N; Whitehouse J; Dawson M
    J Diabetes; 2024 May; 16(5):e13553. PubMed ID: 38664882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.